⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4023326 | 0.67 | — | — | |
| SCHEMBL46494 | 0.65 | — | — | |
| SCHEMBL2067916 | 0.65 | DYRK1A (0.52) | — | |
| SCHEMBL4560704 | 0.65 | DYRK1A (0.52) | — | |
| SCHEMBL974350 | 0.65 | — | — | |
| SCHEMBL31237159 | 0.64 | DYRK1A (0.41) | — | |
| SCHEMBL3962541 | 0.64 | DYRK1A (0.41) | — | |
| Hydrochloric Acid SCHEMBL30128120 | 0.64 | DYRK1A (0.41) | — | |
| Water SCHEMBL29860131 | 0.64 | DYRK1A (0.41) | — | |
| Iodide SCHEMBL9950363 | 0.64 | DYRK1A (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3651762-B1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2024-07-03 | — | — | EP | claimed |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-20220048913-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2022-02-17 | — | — | US | claimed |
| EP-3651762-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2020-05-20 | — | — | EP | claimed |
| EP-3624797-A1 | KINASE INHIBITORS AND USES THEREOF | Denali Therapeutics Inc. (US) | 2020-03-25 | — | — | EP | claimed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | claimed |
| US-RE47689-E1 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | claimed |
| EP-3558969-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2019-10-30 | — | — | EP | claimed |
| WO-2010128995-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | claimed |
| EP-1909792-B1 | SUBSTITUTED PIPERIDINE DERIVATIVES AS SOMATOSTATIN SST1 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-09-02 | — | — | EP | claimed |
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | PFIZER INC | 2009-02-05 | — | — | US | claimed |
| US-20090005390-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S | 2009-01-01 | — | — | US | claimed |
| EP-1989196-A2 | MELANOCORTIN TYPE 4 RECEPTOR AGONIST PIPERIDINOYLPYRROLIDINES | Pfizer Limited (GB) | 2008-11-12 | — | — | EP | claimed |
| WO-2007096763-A2 | MELANOCORTIN TYPE 4 RECEPTOR AGONIST PIPERIDINOYLPYRROLIDINES | PFIZER LIMITED (GB) | 2007-08-30 | — | — | WO | claimed |
| US-20050245567-A1 | Novel quinuclidine derivatives and their use | NEUROSEARCH A/S (DK) | 2005-11-03 | — | — | US | claimed |
| EP-1532144-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2005-05-25 | — | — | EP | claimed |
| WO-2004016608-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2004-02-26 | — | — | WO | claimed |
| WO-1996023798-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-08 | — | — | WO | claimed |